Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin

Amyloid

Volumn 23, Issue 2, 2016, Pages 86-97

  Higaki, Jeffrey N ^a   Chakrabartty, Avi ^b   Galant, Natalie J ^b   Hadley, Kevin C ^b   Hammerson, Bradley ^c   Nijjar, Tarlochan ^a   Torres, Ronald ^a   Tapia, Jose R ^a   Salmans, Joshua ^a   Barbour, Robin ^a   Tam, Stephen J ^a   Flanagan, Ken ^a   Zago, Wagner ^a   Kinney, Gene G ^a  

^a Prothena Biosciences Inc   (United States)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c SEATTLE GENETICS INC   (United States)

Author keywords

Aggregation; cardiac; clearance; cryptotope; fibrils; immunotherapy; protein misfolding

Indexed keywords

AMYLOID PROTEIN; MONOCLONAL ANTIBODY; PREALBUMIN; ANTIGEN ANTIBODY COMPLEX; EPITOPE; PROTEIN AGGREGATE; RECOMBINANT PROTEIN;

AMYLOIDOSIS; ANTIBODY LABELING; ARTICLE; CHOROID PLEXUS; EPIFLUORESCENCE MICROSCOPY; HEART AMYLOIDOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER; MACROPHAGE; PANCREAS; PH; PHAGOCYTOSIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FOLDING; SURFACE PLASMON RESONANCE; TRANSTHYRETIN AMYLOIDOSIS; WESTERN BLOTTING; AMINO ACID SEQUENCE; ANIMAL; ANTIGEN ANTIBODY COMPLEX; BIOSYNTHESIS; CARDIAC MUSCLE; CARDIOMYOPATHY; CELL CLONE; CELL LINE; CHEMISTRY; COMPLICATION; CYTOLOGY; FAMILIAL AMYLOID POLYNEUROPATHY; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MOUSE; PATHOLOGY; PHAGOCYTE;

AMINO ACID SEQUENCE; AMYLOID NEUROPATHIES, FAMILIAL; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; CARDIOMYOPATHIES; CELL LINE; CLONE CELLS; EPITOPES; HUMANS; MICE; MYOCARDIUM; PHAGOCYTES; PHAGOCYTOSIS; PREALBUMIN; PROTEIN AGGREGATES; PROTEIN CONFORMATION; PROTEIN FOLDING; RECOMBINANT PROTEINS;

EID: 84961203344     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2016.1148025     Document Type: Article

References (45)

1. G.Merlini, D.C.Seldin, M.A.Gertz Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011;29:1924–33
2. M.Ueda, Y.Ando Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener 2014;3:19
3. Y.Sekijima Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 2015;86:1036–43
4. D.M.Rowczenio, I.Noor, J.D.Gillmore, H.J.Lachmann, C.Whelan, P.N.Hawkins, L.Obici,. Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat 2014;35:E2403–12
5. L.H.Connors, A.Lim, T.Prokaeva, V.A.Roskens, C.E.Costello Tabulation of human transthyretin (TTR) variants, 2003. Amyloid 2003;10:160–84
6. Y.Ando, T.Coelho, J.L.Berk, M.W.Cruz, B.G.Ericzon, S.Ikeda, W.D.Lewis,. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 2013;8:31
7. P.Westermark, K.Sletten, B.Johansson, G.G.CornwellIII Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. U.S.A. 1990;87:2843–5
8. J.L.Sikora, M.W.Logue, G.G.Chan, B.H.Spencer, T.B.Prokaeva, C.T.Baldwin, D.C.Seldin,. Genetic variation of the transthyretin gene in wild-type transthyretin amyloidosis (ATTRwt). Hum Genet 2015;134:111–21
9. T.Coehlo, B.G.Erikson, R.Falk, D.Grogan, S.I.Ikeda, M.Mauer, V.Planté-Bordeneuve,. A physician's guide to transthyretin amyloidosis. Amyloidosis Foundation; c2008
10. G.Holmgren, B.G.Ericzon, C.G.Groth, L.Steen, O.Suhr, O.Andersen, B.G.Wallin,. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993;341:1113–16
11. C.E.Bulawa, S.Connelly, M.DeVit, L.Wang, C.Weigel, J.A.Fleming, J.Packman,. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl. Acad. Sci. U.S.A. 2012;109:9629–34
12. T.Coelho, L.F.Maia, A.Martins da Silva, C.M.Waddington, V.Planté-Bordeneuve, P.Lozeron, O.B.Suhr,. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012;79:785–92
13. J.L.Berk, O.B.Suhr, L.Obici, Y.Sekijima, S.R.Zeldenrust, T.Yamashita, M.A.Heneghan,. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. Jama 2013;310:2658–67
14. T.Coelho, D.Adams, A.Silva, P.Lozeron, P.N.Hawkins, T.Mant, J.Perez,. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med 2013;369:819–29
15. E.J.Ackermann, S.Guo, S.Booten, L.Alvarado, M.Benson, S.Hughes, B.P.Monia Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012;19:43–4
16. G.Arsequell, A.Planas Methods to evaluate the inhibition of TTR fibrillogenesis induced by small ligands. Curr Med Chem 2012;19:2343–55
17. M.Kanai, A.Raz, D.S.Goodman Retinol-binding protein: the transport protein for vitamin A in human plasma. J Clin Invest 1968;47:2025–44
18. X.Jiang, J.N.Buxbaum, J.W.Kelly The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA. 2001;98:14943–8
19. J.W.Kelly Alternative conformations of amyloidogenic proteins govern their behavior. Curr Opin Struct Biol 1996;6:11–17
20. E.De Genst, A.Messer, C.M.Dobson Antibodies and protein misfolding: from structural research tools to therapeutic strategies. Biochim Biophys Acta 2014;1844:1907–19
21. J.S.Wall, S.J.Kennel, A.Williams, T.Richey, A.Stuckey, Y.Huang, S.Macy,. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One 2012;7:e52686
22. K.Obayashi, M.Tasaki, H.Jono, M.Ueda, S.Shinriki, Y.Misumi, T.Yamashita,. Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine. Clin Chim Acta 2013;419:127–31
23. S.A.Planque, Y.Nishiyama, M.Hara, S.Sonoda, S.K.Murphy, K.Watanabe, Y.Mitsuda,. Physiological IgM class catalytic antibodies selective for transthyretin amyloid. J Biol Chem 2014;289:13243–58
24. H.Terazaki, Y.Ando, R.Fernandes, K.Yamamura, S.Maeda, M.J.Saraiva Immunization in familial amyloidotic polyneuropathy: counteracting deposition by immunization with a Y78F TTR mutant. Lab Invest 2006;86:23–31
25. Å.Gustavsson, U.Engström, P.Westermark Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloid fibrils and within in situ tissue localizations. Am J Pathol 1994;144:1301–11
26. C.Redondo, A.M.Damas, M.J.M.Saraiva Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity. Biochem J 2000;348:167–72
27. M.Phay, V.Blinder, S.Macy, M.J.Greene, D.C.Wooliver, W.Liu, A.Planas,. Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils. Rejuvenation Res 2014;17:97–104
28. Y.Su, H.Jono, M.Torikai, A.Hosoi, K.Soejima, J.Guo, M.Tasaki,. Antibody therapy for familial amyloidotic polyneuropathy. Amyloid 2012;19:45–6
29. G.Goldsteins, H.Persson, K.Andersson, A.Olofsson, I.Dacklin, Å.Edvinsson, M.J.Saraiva,. Exposure of cryptic epitopes on transthyretin only in amyloid and in amyloidogenic mutants. Proc. Natl. Acad. Sci. U.S.A. 1999;96:3108–13
30. C.Redondo, A.M.Damas, A.Olofsson, E.Lundgren, M.J.M.Saraiva Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils. J Mol Biol 2000;304:461–70
31. A.R.Hurshman Babbes, E.T.Powers, J.W.Kelly Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. Biochemistry 2008;47:6969–84
32. X.Jiang, C.S.Smith, H.M.Petrassi, P.Hammarström, J.T.White, J.C.Sacchettini, J.W.Kelly An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 2001;40:11442–52
33. M.L.Schmidt, K.A.Robinson, V.M.Lee, J.Q.Trojanowski Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. Am J Pathol 1995;147:503–15
34. Y.Sun, P.E.Arslan, A.Won, C.M.Yip, A.Chakrabartty Binding of TDP-43 to the 3'UTR of its cognate mRNA enhances its solubility. Biochemistry 2014;53:5885–94
35. M.Wogulis, S.Wright, D.Cunningham, T.Chilcote, K.Powell, R.E.Rydel Nucleation-dependent polymerization is an essential component of amyloid-mediated neuronal cell death. J Neurosci 2005;25:1071–80
36. W.-F.Xue, S.W.Homans, S.E.Radford Systematic analysis of nucleation-dependent polymerization reveals new insights into the mechanism of amyloid self-assembly. Proc. Natl. Acad. Sci. U.S.A. 2008;105:8926–31
37. B.Solomon, R.Koppel, D.Frankel, E.Hanan-Aharon Disaggregation of Alzheimer beta-amyloid by site-directed mAb. Proc Natl Acad Sci USA 1997;94:4109–12
38. L.Saelices, L.M.Johnson, W.Y.Liang, M.R.Sawaya, D.Cascio, P.Ruchala, J.Whitelegge,. Uncovering the mechanism of aggregation of human transthyretin. J Biol Chem 2015;290:28932–43
39. F.Bard, C.Cannon, R.Barbour, R.-L.Burke, D.Games, H.Grajeda, T.Guido,. Peripherally administered antibodies against amyloid β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000;6:916–19
40. R.Hrncic, J.Wall, D.A.Wolfenbarger, C.L.Murphy, M.Schell, D.T.Weiss, A.Solomon Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol 2000;157:1239–46
41. M.B.Pepys, R.F.Dyck, F.C.de Beer, M.Skinner, A.S.Cohen Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol 1979;38:284–93
42. A.C.Teixeira, M.J.Saraiva Presence of N-glycosylated transthyretin in plasma of V30M carriers in familial amyloidotic polyneuropathy: an escape from ERAD. J Cell Mol Med 2013;17:429–35
43. Y.Sekijima, R.L.Wiseman, J.Matteson, P.Hammarström, S.R.Miller, A.R.Sawkar, W.E.Balch,. The biological and chemical basis for tissue-selective amyloid disease. Cell 2005;121:73–85
44. M.Gertz, H.Landau, R.L.Comenzo, D.Seldin, B.Weiss, J.Zonder, G.Merlini,. First in human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. J Clin Oncol 2016; [Epub ahead of print]. DOI: 10.1200/JCO.2015.63.6530
45. F.L.Ruberg, J.L.Berk Transthyretin (TTR) cardiac amyloidosis. Circulation 2012;126:1286–300